fda decision tirzepatide approval for Zepbound: FSU researcher available for context on newly approved weight loss treatment FDA reviews decision to put

65 NaryzhnyS

Four weeks at 0.25mg uses 0.4mL

An Oculoplastics Surgeon Explains How to Fix It Over the last few years, certain treatments originally developed for type 2 diabetes and obesity have transformed the way people lose weight

South Korea 8.6.7

Common, expected injection site reactions include: Redness or erythema at the injection site Mild swelling or oedema Bruising or haematoma formation Itching or mild discomfort Small, firm nodules beneath the skin (particularly if sites are not rotated) These reactions are typically self-limiting

A second Phase I study in adults with diabetic kidney disease reported a D+Q dependent clearance of senescent adipose and skin cells and reduced SASP within 11 days of treatment (106)